Blood‐based biomarkers for Alzheimer’s disease among ethnoracial minority samples – a scoping review
Amanda Leisgang Osse, Amy Nguyen, Stacey Moeller, Jeffrey L Cummings, Jefferson W Kinney, Samantha E John · 2025
Read Blood‐based biomarkers for Alzheimer’s disease among ethnoracial minority samples – a scoping review by Amanda Leisgang Osse, Amy Nguyen, Stacey Moeller, Jeffrey L Cummings, Jefferson W Kinney, Samantha E John (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11716759.txt.
Description
Amanda Leisgang Osse and co-authors review blood tests for Alzheimer's disease in minority groups in a 2025 paper. About 6.7 million older Americans live with the disease. Black Americans face twice the risk of white peers, and Hispanic Americans about one and a half times. Blood markers promise cheaper, easier diagnosis, but most studies drew on majority samples.
Their scoping review searched three databases for marker studies in Black and Hispanic groups. The state of that evidence decides whether the new tests will serve those at highest risk or repeat old gaps. Summarizing what exists, and what is missing, sets the agenda for fairer validation work.
Catalog record
| CREATOR | Amanda Leisgang Osse, Amy Nguyen, Stacey Moeller, Jeffrey L Cummings, Jefferson W Kinney, Samantha E John |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |